Media

Latest press releases, media assets and global media contacts

All press releases Annual Report 2021 (PDF - 4.8MB)
Data centre employee
Close Video

Scroll to explore

Press releases

Search our corporate press releases by keyword or date. You can also visit our market websites for press releases from our local operating companies.

06 February 2023

GSK announces results from 17-year retrospective study on US clinical trial diversity

01 February 2023

Jesduvroq (daprodustat) approved by US FDA for anaemia of chronic kidney disease in adults on dialysis

01 February 2023

GSK delivers strong 2022 performance with full year sales of £29.3 billion +19% AER, +13% CER; Total EPS 371.4p >100% Adjusted EPS of 139.7p +27% AER, +15% CER from continuing operations

01 February 2023

Benlysta granted Orphan Drug Designation by US FDA for the potential treatment of systemic sclerosis
Press releases Other markets
Colleagues in conversation

Media Contacts

Are you a professional journalist with an enquiry for our media team?

Get in touch

Media library

Explore our images and videos for use in the media. 

Lab machine

Image

Equipment assembling respiratory medicine

R&D laboratory

Image

R&D laboratory

Colleagues working in a lab

Image

Scientists working in R&D laboratory

Lady working in a fume cupboard

Image

Scientist using syringe behind protective screen

Gsk House Brentford

Image

GSK House

Dame Emma Walmsley

Image

Dame Emma Walmsley

Our media library

Latest news and reports

2022 Full year and fourth quarter results announcement

Quarterly results
01 February 2023

We announced our full year and fourth quarter results for the period ended 31 December 2022 on Wednesday 1 February.

 

Two lab workers carrying out tasks

Our response to the situation in Ukraine

Learn more

Alongside the global community, we share deep concern about the tragic events happening in Ukraine. We are taking actions guided by our purpose, and as a company dedicated to health and care for people and patients.

Covid-19 virus

Our response to Covid-19

Learn more

Since the pandemic began, we have sought ways to harness our scientific expertise and technology to make a difference. Together with our partners we are developing COVID-19 therapeutics and vaccines, and now have assets at various stages of development, including two approved for use (in some markets).

Continue to Careers

Back to top